COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00844402
Recruitment Status : Completed
First Posted : February 16, 2009
Last Update Posted : February 16, 2009
Information provided by:
Medical University of Graz

Brief Summary:
Primary biliary cirrhosis (PBC) is frequently associated with hypercholesterolemia and possibly with an increased cardiovascular morbidity and mortality. Statins lower serum cholesterol levels and may thus improve the cardiovascular risk in PBC patients. The aim of our study therefore was to prospectively examine the efficacy of low-dose atorvastatin on indicators of cardiovascular risk such as dyslipidemia and vascular function as well as safety in patients with PBC.

Condition or disease Intervention/treatment Phase
Primary Biliary Cirrhosis Hypercholesterolemia Drug: Atorvastatin Phase 3

Detailed Description:
Primary biliary cirrhosis (PBC) is often associated with abnormalities in serum lipids. Hypercholesterolemia is an established risk factor for cardiovascular morbidity and mortality. Since many PBC patients have a very slow progression of their underlying liver disease cardiovascular risk factors may become more relevant as prognostic facors. Whether statins lower serum cholesterol levels and reduce the cardiovascular risk in PBC patients remains to be determined. Statins are generally well tolerated and are not associated with an increased risk of hepatotoxicity in patients with nonalcoholic fatty liver disease (NAFLD). However only limited data on safety on statins in chronic cholestatic liver diseases are available. In a recent pilot study at the Medical University of Graz atorvastatin did not statistically increase liver enzymes in PBC patients. However, data on long-term treatment with atorvastatin in these patients are not yet available. Moreover, long-term treatment with statins may have potential beneficial immunomodulatory effects on the disease course of PBC in analogy to other immune-mediated disorders such as rheumatoid arthritis and multiple sclerosis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis
Study Start Date : January 2006
Actual Primary Completion Date : November 2007
Actual Study Completion Date : November 2007

Arm Intervention/treatment
Experimental: Atorvastatin
Atorvastatin 10 mg per day for 48 weeks
Drug: Atorvastatin
oral, 10 mg, daily, 48 weeks
Other Name: Sortis10 mg, 1-21927, C10AA05

Primary Outcome Measures :
  1. Low-density lipoprotein cholesterol (LDL-C) [ Time Frame: week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 60 ]

Secondary Outcome Measures :
  1. Intima-media thickness of the common carotid artery (IMT), vascular wall stiffness (stiffness index SI), flow-mediated dilation of the brachial artery (FMD) [ Time Frame: week 0, 48 ]
  2. Total cholesterol, triglycerides, VLDL-C, HDL-C, lipid profile, hs-CRP, AP, GGT, bilirubin, bile acids, immunoglobins [ Time Frame: week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 60 ]
  3. AST, ALT, CK, PZ, AT, albumin, creatinine, blood cell count [ Time Frame: week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 60 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • LDL-cholesterol > 130 mg/dl
  • Primary biliary cirrhosis (AMA positive or biopsy proven)
  • Male or female gender
  • Age 18-70 years
  • Normal kidney function

Exclusion Criteria:

  • Primary biliary cirrhosis Stage III-IV (Ludwig Score)
  • Liver cirrhosis
  • Decompensated liver disease ( > Child-Pugh class B, ascites, esophageal varices)
  • ALT or AST > 2x ULN
  • Pregnancy or breastfeeding
  • Premenopausal women without certain contraception
  • Known hypersensitivity to HMG-CoA reductase inhibitors
  • Current treatment with lipid-lowering agents other than atorvastatin; immunosuppressants, macrolides

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00844402

Layout table for location information
Department of Internal Medicine, Medical University of Graz
Graz, Austria, 8036
Sponsors and Collaborators
Medical University of Graz
Layout table for investigator information
Principal Investigator: Michael Trauner, M.D. Medical University of Graz, Department of Internal Medicine
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prof. Dr. Michael Trauner, Medical University of Graz, Department of Internal Medicine Identifier: NCT00844402    
Other Study ID Numbers: MT_PBC-2
First Posted: February 16, 2009    Key Record Dates
Last Update Posted: February 16, 2009
Last Verified: February 2009
Keywords provided by Medical University of Graz:
Vascular function
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Liver Cirrhosis, Biliary
Pathologic Processes
Liver Diseases
Digestive System Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Cholestasis, Intrahepatic
Bile Duct Diseases
Biliary Tract Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors